Develop and test methods for the standardization of immunoassays and mass-spectrometry/single reaction monitoring assay or other methodologies for CSF abeta & tau and other biomarkers as they become clinically applicable.
Develop and test methods for standardization of collection and analysis of MRI and PET neuroimaging data.
Establish CLIA laboratory qualifications in US & the equivalent certification in the EU for at least one CSF biomarker.
Establish qualification of at least one neuroimaging biomarker for use in clinical trials by the FDA and/or the EMA.
2014 to 2021
Research Implementation Area
B. Diagnosis, Assessment and Disease Monitoring
Activities, Funding Initiatives, and Resources
NIH Alzheimer’s Disease Neuroimaging Initiative (ADNI)
NIH PAR-13-148: Biomarkers for Older Controls at Risk for Dementia (BIOCARD) St…
NIH PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting…
NIH RFA-AG-15-011: Biomarkers of Alzheimer's Disease in Down Syndrome (R01)
NIH PA-16-091: Small Business Alzheimer's Disease Research (R43/R44)
NIH PA-16-092: Small Business Alzheimer's Disease Research (R41/R42)
NIH RFA-AG-16-019: Limited Competition: Alzheimer's Disease Neuroimaging Initia…
NIH PAR-18-183: T1 Translational Research on Aging: Small Business Innovation A…
NIH PAS-18-188: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-…